专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120004251A1 USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY 有权
标题翻译：利多卡因胆碱（CBDV）在治疗急性胰腺炎中的应用
公开(公告)号：US20120004251A1
公开(公告)日：2012-01-05
申请号：US13075873
申请日：2011-03-30
申请人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
发明人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
IPC分类号： A61K31/515 , A61P25/08 , A61K31/4015 , A61K31/19 , A61K31/05 , A61K31/352
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K31/515 , A61K36/185 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
摘要翻译：本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

2. 发明授权

US09125859B2 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy 有权
标题翻译：使用植物大麻素大麻素（CBDV）治疗癫痫
公开(公告)号：US09125859B2
公开(公告)日：2015-09-08
申请号：US13075873
申请日：2011-03-30
申请人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
发明人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
IPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K36/185 , A61K45/06
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K31/515 , A61K36/185 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
摘要翻译：本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

3. 发明授权

US06187774B1 Fused heterocyclic compounds and pharmaceutical applications thereof 失效
标题翻译：稠合杂环化合物及其药物应用
公开(公告)号：US06187774B1
公开(公告)日：2001-02-13
申请号：US09142203
申请日：1998-09-03
申请人： Hiroshi Tanaka , Takanobu Kuroita , Yoshifumi Togo , Seigo Ishibuchi , Masakazu Fujio , Takashi Futamura
发明人： Hiroshi Tanaka , Takanobu Kuroita , Yoshifumi Togo , Seigo Ishibuchi , Masakazu Fujio , Takashi Futamura
IPC分类号： A61K31416
CPC分类号： C07D413/06 , C07D209/14 , C07D231/54 , C07D231/56 , C07D261/20 , C07D401/04 , C07D401/06 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
摘要： The present invention relates to a fused heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, and a medicament containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the present invention is a useful antipsychotic agent effective not only for positive symptoms centering on hallucination and delusion characteristic of the acute stage of schizophrenia, but also negative symptoms of apathy, abulia and autism. The inventive compound is expected to make a highly safe antipsychotic agent associated with less side effects, such as extrapyramidal symptoms and endocrine disturbance, which are observed when a conventional antipsychotic agent having a D2 receptor blocking action is administered. Therefore, the inventive compound can be used as a therapeutic agent for the diseases such as schizophrenia.
摘要翻译：本发明涉及式（I）的稠合杂环化合物，其中每个符号如说明书中所定义，其光学异构体，其药学上可接受的盐，含有式（I）化合物的药物组合物，其光学异构体或其药学上可接受的盐和药学上可接受的添加剂，以及含有式（I）化合物，其光学异构体或其药学上可接受的盐的药物。本发明的化合物是一种有效的抗精神病药物，不仅有益于以精神分裂症急性期的幻觉和妄想为特征的阳性症状，而且还有冷漠，厌食和自闭症的阴性症状。预期本发明化合物可以制备与当具有D2受体阻断作用的常规抗精神病药物被施用时观察到的较少副作用（如锥体外系症状和内分泌紊乱）的抗精神病药物。因此，本发明化合物可以用作精神分裂症等疾病的治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式